Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2020 | NSCLC | Editorial

Evaluating response to immunotherapy with ¹⁸F-FDG PET/CT: where do we stand?

Authors: Nicolas Aide, Michel De Pontdeville, Egesta Lopci

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2020

Excerpt

In this issue of the EJNMMI, Seban et al. [1] propose a prognostic score combining baseline total metabolic tumor volume (TMTV) and the Derived Neutrophil-to-Lymphocyte Ratio (dLNR) to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving immune-checkpoint inhibitors (ICI). In their series of 80 patients, a TMTV >75 and a dLNR >3, previously validated as a biomarker of immune activation by other groups [2], resulted as independent predictive factors for shorter OS and worse clinical benefit, the later one established according to RECIST 1.1 criteria and combining objective response (partial or complete) at any time during the course of ICI or stable disease after 6 months of treatment. The same group from Gustave Roussy Institute, had shown in melanoma patients that baseline ¹⁸F-FDG PET parameters could be used to build a prognostic metabolic score using not only the TMTV but also hematopoietic tissue metabolism, namely, bone marrow to liver ratio (BLR) proving that these PET metrics had significant and independent value in predicting survival [3]. Hence, high-risk patients (high TMTV and high BLR) had worse survival compared to low-risk patients (low TMTV and low BLR). In this cohort, BLR not only outperformed spleen to liver ratio (SLR), which has been showed by others groups to predict OS in melanoma [4] but was additionally associated with transcriptomics profiles, including regulatory T cells markers. …

Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04615-x.

Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27:732–8. https://doi.org/10.1093/annonc/mdw016.CrossRefPubMed

Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298–310. https://doi.org/10.1007/s00259-019-04411-7.CrossRefPubMed

Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44:67–77. https://doi.org/10.1007/s00259-017-3691-7.CrossRefPubMed

Castello A, Rossi S, Toschi L, Mazziotti E, Lopci E. Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of (18)F-FDG PET/CT. J Nucl Med: Off Publ, Soc Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.237768.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61. https://doi.org/10.1007/s00259-016-3425-2.CrossRefPubMed

Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging. 2018;45:1072–5. https://doi.org/10.1007/s00259-018-3988-1.CrossRefPubMed

Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, et al. (18)F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. Sci Rep. 2019;9:13362. https://doi.org/10.1038/s41598-019-50079-2.CrossRefPubMedPubMedCentral

Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–83. https://doi.org/10.1007/s00259-017-3870-6.CrossRefPubMed

10.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med: Off Publ, Soc Nucl Med. 2017;58:1421–8. https://doi.org/10.2967/jnumed.116.188839.CrossRef

11.

Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9:8. https://doi.org/10.1186/s13550-019-0473-1.CrossRefPubMedPubMedCentral

12.

Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46:238–50. https://doi.org/10.1007/s00259-018-4171-4.CrossRefPubMed

13.

Ito K, Teng R, Schoder H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET/CT for monitoring of Ipilimumab therapy in patients with metastatic melanoma. Journal of nuclear medicine : official publication. Soc Nucl Med. 2019;60:335–41. https://doi.org/10.2967/jnumed.118.213652.CrossRef

14.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profile of Nivolumab and Ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35:3815–22. https://doi.org/10.1200/jco.2016.72.1167.CrossRef

15.

Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, et al. (18)FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04573-4.

16.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019;125:3208–18. https://doi.org/10.1002/cncr.32190.CrossRefPubMed

17.

Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, et al. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer. 2019;20:178–85.e2. https://doi.org/10.1016/j.cllc.2019.02.001.CrossRefPubMed

18.

Hicks RJ, Iravani A, Sandhu S. (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond. PET Clin. 2020;15:11–22. https://doi.org/10.1016/j.cpet.2019.08.007.CrossRefPubMed

Title: Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?
Authors: Nicolas Aide
Michel De Pontdeville
Egesta Lopci
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Checkpoint Inhibitors
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04702-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluating response to immunotherapy with ¹⁸F-FDG PET/CT: where do we stand?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2020

McCune-Albright syndrome confirmed by 99mTc-MDP

Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy

Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study

Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—results from a prospective trial

18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients

The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study